Effects of STI571 (gleevec) on pancreatic cancer cell growth
© Li et al; licensee BioMed Central Ltd. 2003
Received: 05 September 2003
Accepted: 17 September 2003
Published: 17 September 2003
Pancreatic cancer is an aggressive malignancy characterized by low responsiveness to chemotherapy and radiotherapy. This resistance is partly due to the overexpression of several tyrosine kinase receptors and their ligands. STI571 has specific activity in inhibiting c-kit, PDGF and Abl receptor tyrosine kinases and has proven successful in the treatment of CML and GIST patients. Here, we investigated the potential role of STI571 in pancreatic cancer.
The GI50 of STI571 as well as the effects of STI571 on growth factor actions in pancreatic cell lines were analyzed using the MTT assay. FACS analysis using Annexin and PI staining was performed to study cell cycle, apoptosis, and cell death. Western blot analysis was carried out to investigate MAP kinase and receptor tyrosine kinase phosphorylation. STI571 inhibited cell proliferation in pancreatic cancer cell lines with GI50 concentrations ranging from 17 to 31.5 microM. EGF, IGF-1, and FGF-2 but not PDGF exerted growth stimulatory effects in pancreatic cancer cell lines. STI571 only partly blocked these effects on cell growth, and did not abrogate growth factor-induced receptor and MAPK phosphorylation.
Our data demonstrate that STI571 inhibits pancreatic cancer cell growth with high GI50 concentrations through tyrosine-kinase receptor independent pathways. The clinical application of STI571 in pancreatic cancer is therefore rather doubtful.
Although pancreatic cancer has an incidence of only about 10 cases/100,000 persons, it is the fourth to fifth leading cause of cancer-related deaths in the Western world . Most of the newly diagnosed patients present at an already unresectable tumor stage. The 5-year survival rate of these patients is less than 1% [2–4] and the median survival time is approximately 5–6 months after tumor detection. One of the reasons for this is that conventional oncological strategies, such as chemotherapy, radiotherapy, antihormonal modalities or systemic use of monoclonal antibodies, have not achieved significant improvement in the survival of pancreatic cancer patients [5–9].
In recent years, increasing attention has been directed towards the role of growth factors in the pathogenesis of human tumors. Human pancreatic cancers overexpress a number of important tyrosine kinase growth factor receptors and their ligands, such as those belonging to the epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF-1), and vascular endothelial growth factor (VEGF) families [10, 11]. In addition, expression of both PDGF and PDGF receptors (PDGFRs) has been observed in pancreatic cancer . It is thought that these growth factors act in an autocrine and/or paracrine manner to stimulate pancreatic cancer growth. Binding of growth factors to their receptors results in receptor autophosphorylation and subsequent signal transduction via an array of different molecules.
Small molecule drugs that can selectively inhibit tyrosine kinases are likely to be of benefit in a number of neoplastic diseases. Although tyrosine kinase inhibitors have been studied for many years, they often had little specificity and thus were unlikely to be suitable for clinical applications. Recently, more selective tyrosine kinase inhibitors have been developed, one of them being STI571 (Gleevec, imatinib mesylate and also known as CGP57148B; Novartis Pharmaceuticals). STI571 belongs to the 2-phenylaminopyrimidine class, and has selectivity for Abl, PDGF receptor [13–15] and c-kit receptor tyrosine kinases . The effectiveness of this drug in blocking Bcr-Abl and c-kit tyrosine kinases has led to Food and Drug Administration (FDA) approval for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and c-kit-positive gastrointestinal stromal tumors.
It has been shown recently that the stem cell factor (SCF) and its receptor c-kit are present in both normal and pancreatic cancer tissues, and that SCF has no growth-promoting effect in pancreatic cancer cells. Nevertheless, STI571 could inhibit pancreatic cell growth dose-dependently . Since most human pancreatic cancer tissues express PDGFR, STI571 might exert its function through this pathway in pancreatic cancer cells. The purpose of this study was to gain insight into the mechanisms of STI571 action in pancreatic cancer cells, with special emphasis on receptor tyrosine kinase signaling.
Determination of the GI50 concentration of STI571 in pancreatic cancer cells
GI50 concentration of STI571 in different cancer cell lines in comparison to STI571 plasma concentrations. # as determined in complete medium.
Mechanism of STI 571 action on pancreatic cancer cells
Effects of STI571 on growth factor-induced proliferation of pancreatic cancer cells
Effects of STI571 on growth factor-induced receptor and MAP kinase activation
To summarize, pancreatic cancer cells, resistant to growth induction through STI571-sensitive c-kit and PDGF pathways, were still responsive to the inhibitory effects of STI571, although at high GI50 concentrations. Since cell cycle distribution as well as growth factor receptor and MAPK-activation were not disturbed, we assumed that antiproliferative effects of STI571 were apparently of a toxic nature, the exact mechanism of which should be further investigated.
Protein kinases play a crucial role in signal transduction as well as in cellular proliferation, differentiation, and various regulatory mechanisms. Deregulation of those signaling pathways is frequent during malignant transformation. The inhibition of growth-related kinases, especially tyrosine kinases, might provide new tools in the therapy of cancer. The protein tyrosine kinase inhibitor STI571, which has been effective in CML as well as GIST, is a selective inhibitor of Abl, PDGF and c-kit receptor tyrosine kinases [13, 14, 20]. This drug has a GI50 for inhibition of Bcr-Abl kinase activity of 0.25 μM and inhibits the growth of cell lines which are dependent on Bcr-Abl kinase activity at 1 μM [13, 14]. In addition, STI571 also selectively inhibits the growth of cell lines derived from CML patients, as well as primary CML progenitors in clonogenic assays at low micromolar concentrations [13, 21, 22]. It also efficiently inhibits SCF-mediated c-kit activation at concentrations similar to those that inhibit Bcr-Abl in cellular assays, with a GI50 in the range of 0.1–0.5 μM .
In this study, we sought to extend the profile of STI571 applications, and tested its effects in pancreatic cancer cell lines. The STI571 target c-kit and its ligand stem cell factor (SCF) have been shown to be expressed in pancreatic cancer cells. It has been shown that SCF has no significant effects on pancreatic cancer cell growth , whereas STI571 inhibits pancreatic cancer cell growth . Thus, STI571 may exert its effect on pancreatic cancer cell growth through c-kit-independent pathways. For example, STI571 can inhibit PDGF-mediated growth and leads to the apoptosis of osteosarcoma cells in vitro by selective inhibition of the PDGFR tyrosine kinase .
PDGF was one of the first polypeptide growth factors identified that signals through a cell surface tyrosine kinase receptor (PDGFR) to stimulate various cellular functions, including growth, proliferation, and differentiation. When PDGF binds to the extracellular portion of the receptor, the receptor undergoes dimerization and autophosphorylation with tyrosine kinase activation. To date, PDGF expression has been shown in a number of different solid tumors, from glioblastomas to prostate carcinomas . The biological role of PDGF signaling can vary from autocrine stimulation of cancer cell growth to more subtle paracrine interactions involving adjacent stroma and angiogenesis. In pancreatic cancers, there is a marked increase in the mRNA levels of PDGFR-alpha and PDGFR-beta in comparison with the normal pancreas, and PDGF and both PDGF receptors are present in the cancer cells . Thus, STI571 maybe also inhibit pancreatic cancer cell growth via the PDGF receptor pathway.
In pancreatic cancer, a variety of other growth factors that signal through tyrosine kinase receptors are also expressed at increased levels. For example, the presence of EGFs, FGFs, PDGFs, and IGFs and their respective receptors has been observed in pancreatic cancer, and these growth factors are thought to contribute to its malignant phenotype [10, 11, 24]. For example, it has been reported that the mRNA levels of EGF and EGFR are markedly increased in pancreatic cancer tissues in comparison with the normal pancreas , suggesting that the coexpression of EGFR and its ligands may contribute to the aggressiveness of human pancreatic cancer. FGF and its receptors are also overexpressed in pancreatic cancer tissues and cell lines [26, 27], and cell growth, cell adhesion and invasion are modulated by fibroblast growth factors in pancreatic cancer cell lines [27–29]. IGF-1 and its receptor IGF1R are also overexpressed in pancreatic cancer , and they also have the potential to stimulate pancreatic cancer cell growth.
We have now demonstrated that STI571 has dose-dependent inhibitory effects in all six tested pancreatic cancer cell lines, with GI50 in the range of 17–31.5 μM (10% FCS) and 9–20 μM (1% FCS). Notably, these concentrations are relatively high compared with the concentrations sufficient for the inhibition of Abl and c-kit in other tumors [14, 18, 31]. Thus, when the drug was used in CML patients, the plasma levels of STI571 inducing hematologic and cytogenetic response in patients were reported to be in the range of 0.17–5.68 μM after treatment with 25–600 mg STI571/day . Concentrations of more than 6 μM under cell culture conditions are unlikely to translate into clinical practice, since the adverse effects of the drug will become intolerable for the patients .
In cell cycle analysis we did not see cell cycle change and apoptosis caused by STI571. It has been reported that STI571 did not induce apoptosis in serum-containing medium, and it has been suggested that this is because the cells may be more resistant under these conditions, and serum can persistently activate MAP kinase [16, 33]. Based on these data, we treated cells with STI571 in both complete medium (10% FCS) and 1% FCS medium. No apoptotic cell death was observed under either of these serum concentrations, yet prolongation of STI571 treatment led to more cell death under these conditions. In addition, more Annexin-V-positive cells were also observed, suggesting that STI571 can damage the integrity of the cell membrane, causing phosphatidylserine translocation to the outer surface of the cells, and at a late stage, causing cell death without significant apoptosis. Thus, STI571 may exert its effects on cell growth in an unspecific manner.
STI571 inhibits pancreatic cells growth, but these effects are not mediated through blockage of the PDGF receptor tyrosine kinase, since PDGF did not stimulate pancreatic cancer cell growth and did not lead to MAP kinase or PDGF receptor phosphorylation. In our previous study, we excluded the SCF/c-kit tyrosine kinase receptor pathway as a possible target of STI571 as well . In the present study, we demonstrate that STI571 partially but not specifically blocks EGF, IGF-1 and FGF-2 mitogenic pathways, which have the potential to stimulate pancreatic cancer cell growth. Since STI571 has relatively high GI50 concentrations in pancreatic cancer cells, its action appears to be of toxic origin and its clinical relevance in pancreatic cancer is rather doubtful. Nevertheless, in view of the extremely poor prognosis of patients with pancreatic cancer, and in view of the fact that pancreatic cancer tissues in vivo indeed express both PDGF and c-kit receptor tyrosine kinases, it seems worthwhile to further investigate the therapeutic effects of STI571 in small clinical trials.
Material and Methods
RPMI-1640 DMEM, trypsin-EDTA, and penicillin-streptomycin were purchased from Invitrogen (Karlsruhe, Germany); FBS from PAN Biotech (Aidenbach, Germany); human recombinant PDGF, IGF-1 and FGF-2 from R&D Systems (Abingdon, United Kingdom), and EGF from Upstate Biotechnology (Hamburg, Germany). Phospho-PDGFR-beta (tyr857) and p-EGFR (tyr1173) polyclonal antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Phospho-p44/42 MAPK (Thr202/Tyr204) antibodies were purchased from Cell Signaling Technology (Frankfurt, Germany), anti-rabbit IgG HRPO-linked antibodies and ECL immunoblotting detection reagents from Amersham Biosciences (Amersham Life Science, Amersham, UK), and anti-goat IgG-HPRO peroxidase linked antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Complete mini-EDTA-free protease inhibitor cocktail tablets and Annexin-V-Fluos were purchased from Roche GmbH (Mannheim, Germany). All other reagents were from Sigma Chemical Company (Taufkirchen, Germany). STI571 was kindly provided by Novartis Pharma AG (Basel, Switzerland).
Cell culture and MTT assay
Human pancreatic cancer cell lines were routinely grown in DMEM (Colo-357, and Mia-PaCa-2) or RPMI (Aspc-1, BxPc-3, Capan-1, and T3M4) supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin (complete medium). To assess cell proliferation, the MTT test was employed. Briefly, cells were seeded at a density of 5000 cells/well in 96-well plates, grown overnight and exposed to STI571 alone or in combination with growth factors. After 48 or 72 hours of incubation, 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) was added (50 μg/well) for 4 hours. Formazan products were solubilized with acidic isopropanol, and the optical density was measured at 570 nm. To determine the GI50 of STI571 (the concentration that causes 50% growth inhibition), graded concentrations of STI571 were added to triplicate wells and GI50 was calculated using 100 × (T-T0)/(C-T0) = 50. T is the optical density of the test well after a 48-hour period of exposure to STI571, T0 is the optical density at time zero, and C is the control optical density after 48 hours. All experiments were performed in triplicate.
FACS analysis of cell death and cell cycle
105 pancreatic tumor cells were seeded into 6-well plates in 1% FBS-containing medium, allowed to adhere overnight and then treated with corresponding GI50 concentrations of STI571. To analyze cell cycle distribution, cells were collected after 48 hours of incubation, washed with PBS and resuspended in 0.5 ml of hypotonic PI buffer (5 μg/ml propidium iodide, 0.1% Triton X100 and 0.1% sodium citrate), stored overnight at 4°C and then analyzed by flow cytometry using BD-LSR (Becton Dickinson and Company, New York, USA). The resulting DNA histograms were interpreted using the Cell Quest Pro software (Becton Dickinson and Company, New York, USA). To determine the degree of cell death, cells were collected after 12, 24 and 48 hours of exposure to GI50 of STI571 and were washed and stained with Annexin-V-FITC (apoptotic death) or PI (necrotic death) according to the manufacturer's instructions (Roche, Mannheim, Germany).
Western blot analysis
Cell culture monolayers were washed twice with ice-cold PBS and lysed with buffer containing Tris-HCl (50 mM, pH 7.4), NP-40 (1%), Na-deoxycholate (0.25%), NaCl (150 mM), EDTA (1 mM), PMSF (1 mM), Na3VO4 (1 mM), NaF (1 mM) and one tablet of complete mini-EDTA-free protease inhibitor cocktail (in 10 ml buffer). Protein concentration was determined by the BCA protein assay (Pierce Chemical Co., Rockford, IL, USA). 30 μg of cell lysates were separated on SDS-polyacrylamide gels and electroblotted onto nitrocellulose membranes. Membranes were then incubated in blocking solution (5% nonfat-milk in 20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) (TBS-T), followed by incubation with the indicated antibodies at 4°C overnight. The membranes were then washed in TBS-T and incubated with HRPO-conjugated secondary antibodies for 1 hour at room temperature. Antibody detection was performed with an enhanced chemiluminescence reaction.
Results were expressed as mean ± SEM. For statistical analysis, the Student's t test was used. Significance was defined as p < 0.05.
- Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin. 2002, 52: 23-47.View ArticlePubMedGoogle Scholar
- Coppola D: Molecular prognostic markers in pancreatic cancer. Cancer Control. 2000, 7: 421-427.PubMedGoogle Scholar
- Gudjonsson B: Cancer of the pancreas. 50 years of surgery. Cancer. 1987, 60: 2284-2303.View ArticlePubMedGoogle Scholar
- Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med. 1992, 326: 455-465.View ArticlePubMedGoogle Scholar
- Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol. 2002, 29: 9-16. 10.1053/sonc.2002.37372View ArticlePubMedGoogle Scholar
- van der Schelling GP, Jeekel J: Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile?. World J Surg. 1999, 23: 950-953. 10.1007/s002689900605View ArticlePubMedGoogle Scholar
- Friess H, Buchler M, Kruger M, Beger HG: Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas. 1992, 7: 516-521.View ArticlePubMedGoogle Scholar
- Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, Beger HG: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas. 1993, 8: 540-545.View ArticlePubMedGoogle Scholar
- Buchler M, Friess H, Schultheiss KH, Gebhardt C, Kubel R, Muhrer KH, Winkelmann M, Wagener T, Klapdor R, Kaul M, : A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer. 1991, 68: 1507-1512.View ArticlePubMedGoogle Scholar
- Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 1998, 7: 25-41.PubMedGoogle Scholar
- Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW: Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen. 2001, 21: 27-44. 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9View ArticlePubMedGoogle Scholar
- Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, Korc M: Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer. 1995, 62: 529-535.View ArticlePubMedGoogle Scholar
- Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2: 561-566.View ArticlePubMedGoogle Scholar
- Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997, 90: 4947-4952.PubMedGoogle Scholar
- McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M: Inhibition of Platelet-derived Growth Factor-mediated Proliferation of Osteosarcoma Cells by the Novel Tyrosine Kinase Inhibitor STI571. Clin Cancer Res. 2002, 8: 3584-3591.PubMedGoogle Scholar
- Krystal GW, Honsawek S, Litz J, Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000, 6: 3319-3326.PubMedGoogle Scholar
- Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, Iorio M, Bevilacqua G, Buchler MW, Friess H: The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest. 2002, 82: 1481-1492.View ArticlePubMedGoogle Scholar
- Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000, 19: 3521-3528. 10.1038/sj.onc.1203698View ArticlePubMedGoogle Scholar
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344: 1031-1037. 10.1056/NEJM200104053441401View ArticlePubMedGoogle Scholar
- Okuda K, Weisberg E, Gilliland DG, Griffin JD: ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001, 97: 2440-2448. 10.1182/blood.V97.8.2440View ArticlePubMedGoogle Scholar
- Deininger MW, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997, 90: 3691-3698.PubMedGoogle Scholar
- Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190, 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998, 4: 1661-1672.PubMedGoogle Scholar
- Torrisani J, Buscail L: [Molecular pathways of pancreatic carcinogenesis]. Ann Pathol. 2002, 22: 349-355.PubMedGoogle Scholar
- Shi X, Friess H, Kleeff J, Ozawa F, Buchler MW: Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology. 2001, 1: 517-524. 10.1159/000055854View ArticlePubMedGoogle Scholar
- Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992, 90: 1352-1360.PubMed CentralView ArticlePubMedGoogle Scholar
- Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M: Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993, 53: 5289-5296.PubMedGoogle Scholar
- Kornmann M, Beger HG, Korc M: Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas. 1998, 17: 169-175.View ArticlePubMedGoogle Scholar
- Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, Korc M: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998, 102: 1662-1673.PubMed CentralView ArticlePubMedGoogle Scholar
- El-Hariry I, Pignatelli M, Lemoine NR: FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. Int J Cancer. 2001, 94: 652-661. 10.1002/ijc.1515View ArticlePubMedGoogle Scholar
- Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995, 55: 2007-2011.PubMedGoogle Scholar
- Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56: 100-104.PubMedGoogle Scholar
- Zhang P, Gao WY, Turner S, Ducatman BS: Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer. 2003, 2: 1- 10.1186/1476-4598-2-1PubMed CentralView ArticlePubMedGoogle Scholar
- Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001, 61: 5778-5783.PubMedGoogle Scholar
- Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, Mester J, Gespach C: The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 2002, 62: 4879-4883.PubMedGoogle Scholar
- Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S, Bassilian S, Ahmed S, Lee WN, Boros LG: Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem. 2001, 276: 37747-37753.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.